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Introduction: Despite the introduction of novel therapies, high-dose melphalan followed by autologous haematopoietic
cell transplantation (AHCT) remains the standard of care for younger patients with multiple myeloma (MM). There are
limited data on the effects of increased body mass index (BMI) on outcomes from AHCT and, in particular, whether or not
melphalan dose adjustments should be made in patients with increased BMI. We therefore investigated the effect of
increased BMI, and melphalan dose adjustments made for this, on outcomes from AHCT for MM. 
Material (or patients) and methods: We conducted a retrospective study on all patients undergoing their first AHCT for
MM from 2003-2013, and categorised them according to their BMI (normal weight: BMI 18.5-24.9, overweight: BMI 25.0-
29.9, obese: BMI 30.0-34.9 and severely obese: BMI>35.0). We investigated whether BMI group affected CD34+ cell
collection, neutrophil/platelet engraftment, transplant-related mortality (TRM), progression-free (PFS) and overall survival
(OS) rates. We also investigated, in a subgroup of patients with increased BMI, whether melphalan dose adjustments
altered outcomes compared to those in whom no dose adjustments were made.
Results: 320 patients were included: 96 (30%) were normal weight, 143 (45%) overweight, 59 (18%) obese and 22 (7%)
were severely obese. There were no significant differences between BMI groups in numbers of CD34+ cells harvested or
transplanted.  Neutrophil and platelet engraftment times were also not significantly different. The 5-year OS rate was not
significantly different between BMI groups (50.7% for normal weight, 60.9% for overweight, 57.2% for obese and 55% for
severely obese, p=0.97).
Patients  were  then  divided  into  two  groups  according  to  scheduled  melphalan  dose  (200mg/m2,  n  =  223,  and  all  other
doses,  predominantly  140mg/m2,  n=97).  The  median  age  of  those  scheduled  for  200mg/m2  was  lower  than  for  those
scheduled to receive lower doses (57 versus 66 years, p<0.0001), and a higher proportion of patients in the lower dose
group  had  renal  and  cardiac  co-morbidities.  However,  there  was  no  significant  difference  in  2-year  PFS  (49%  versus
52%, p=0.32) or 5-year OS rates (61% versus 49 %, p=0.26) between these groups.
In 43 patients with BMI>27.8 (33% of a total of 132), the melphalan dose was adjusted by the transplant physicians to 85-
96% of that scheduled. Comparison of the dose-adjusted with the non-adjusted group showed no differences in age, sex
or  co-morbidities.  There  were  no  statistically  significant  differences  between  these  groups  in  neutrophil  (median  14.0
versus 13.0 days, p=0.11) and platelet engraftment (median 16.0 versus 17.0 days, p=0.19), 1-year TRM (0% versus 1%,
p=0.81), 2-year PFS (57.1% versus 47.8%, p=0.30) and 5-year OS (61.2% versus 55.3%, p=0.84).
Conclusion: In MM patients undergoing high-dose melphalan with AHCT, increased BMI does not alter CD34+ cell
harvest, time to engraftment, 1-year TRM, 2-year PFS or 5-year OS. Melphalan dose reductions in patients with
increased BMI do not appear to alter key transplant outcomes.  
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